| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
|
Lu Y.-S.; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO; Huang C.-S. |
| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Sung-Hsin Kuo;Hsu C.-H.;Chen L.-T.;Lu Y.-S.;Lin C.-H.;Yeh P.-Y.;Jeng H.-J.;Gao M.;Yeh K.-H.;Cheng A.-L.; SUNG-HSIN KUO; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T.;Yeh P.-Y.;Gao M.;Chen C.-W.;Yeh L.-C.;Feng W.-C.;Sung-Hsin Kuo;Hsu C.-H.;Lu Y.-S.;Cheng A.-L.; Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; SUNG-HSIN KUO; Hsu C.-H.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:28Z |
CYP19 genetic polymorphism haplotype aasa is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer
|
SUNG-HSIN KUO; Yang S.-Y.; Lien H.-C.; Lo C.; Lin C.-H.; Lu Y.-S.; Cheng A.-L.; Chang K.-J.; Huang C.-S. |
| 臺大學術典藏 |
2021-02-23T08:26:24Z |
High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country
|
Lin C.-H.;Shen C.-Y.;Lee J.-H.;Huang C.-S.;Yang C.-H.;Kuo W.-H.;Chang D.-Y.;Hsiung C.-N.;Kuo K.-T.;Chen W.-W.;Chen I.-C.;Wu P.-F.;Sung-Hsin Kuo;Chen C.-J.;Lu Y.-S.;Cheng A.-L.; Lin C.-H.; Shen C.-Y.; Lee J.-H.; Huang C.-S.; Yang C.-H.; Kuo W.-H.; Chang D.-Y.; Hsiung C.-N.; Kuo K.-T.; Chen W.-W.; Chen I.-C.; Wu P.-F.; SUNG-HSIN KUO; Chen C.-J.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:22Z |
Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
|
Lin P.-H.; Kuo W.-H.; Huang A.-C.; Lu Y.-S.; Lin C.-H.; SUNG-HSIN KUO; Wang M.-Y.; Liu C.-Y.; Cheng F.T.-F.; Yeh M.-H.; Li H.-Y.; Yang Y.-H.; Hsu Y.-H.; Fan S.-C.; Li L.-Y.; Yu S.-L.; Chang K.-J.; Chen P.-L.; Ni Y.-H.; Huang C.-S. |
| 臺大學術典藏 |
2021-02-23T08:26:21Z |
Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1?V2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy
|
Lai S.-F.;Chen Y.-H.;Kuo W.-H.;Lien H.-C.;Wang M.-Y.;Lu Y.-S.;Lo C.;Sung-Hsin Kuo;Cheng A.-L.;Huang C.-S.; Lai S.-F.; Chen Y.-H.; Kuo W.-H.; Lien H.-C.; Wang M.-Y.; Lu Y.-S.; Lo C.; SUNG-HSIN KUO; Cheng A.-L.; Huang C.-S. |
| 臺大學術典藏 |
2021-02-23T08:26:16Z |
The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation
|
Lai S.-F.;Chen Y.-H.;Liang T.H.-K.;Hsu C.-Y.;Lien H.-C.;Lu Y.-S.;Huang C.-S.;Sung-Hsin Kuo; Lai S.-F.; Chen Y.-H.; Liang T.H.-K.; Hsu C.-Y.; Lien H.-C.; Lu Y.-S.; Huang C.-S.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-18T08:01:17Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; JA-DER LIANG; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-05T07:26:11Z |
Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer
|
Chen I.-C.; Chang Y.-C.; Lu Y.-S.; KUEI-PIN CHUNG; Huang C.-S.; Lu T.-P.; Kuo W.-H.; Wang M.-Y.; Kuo K.-T.; Wu P.-F.; Hsueh T.-H.; Shen C.-Y.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Kun-Huei Yeh; Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:51Z |
High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine Leiomyosarcoma
|
Kun-Huei Yeh;Lu Y.-S.;Hsiao C.-H.;Cheng A.-L.; KUN-HUEI YEH; Lu Y.-S.; Hsiao C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Kun-Huei Yeh;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.;Shen Y.-C.;Yang C.-H.;Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Liu H.-T.;Li C.-C.;Chen J.-S.;Wu C.-Y.;Cheng A.-L.; Hsu C.; Shen Y.-C.; Yang C.-H.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:49Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Kun-Huei Yeh;Lu Y.S.;Hsu C.H.;Lin J.F.;Chao H.J.;Huang T.C.;Chung C.Y.;Chang C.S.;Yang C.H.;Cheng A.L.; KUN-HUEI YEH; Lu Y.S.; Hsu C.H.; Lin J.F.; Chao H.J.; Huang T.C.; Chung C.Y.; Chang C.S.; Yang C.H.; Cheng A.L. |
| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:47Z |
Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors
|
Lu Y.-S.;Lien H.-C.;Yeh P.-Y.;Kun-Huei Yeh;Kuo M.-L.;Kuo S.-H.;Cheng A.-L.; Lu Y.-S.; Lien H.-C.; Yeh P.-Y.; KUN-HUEI YEH; Kuo M.-L.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.;Cheng A.-L.;Hsu C.-H.;Lu Y.-S.;Hsu C.;Kun-Huei Yeh;Wu C.-Y.;Huang C.-S.;Yang C.-H.; Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; KUN-HUEI YEH; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:44Z |
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells
|
Chen K.-F.; Yeh P.-Y.; KUN-HUEI YEH; Lu Y.-S.; Huang S.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:43Z |
Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation
|
Lin P.-H.;Lu Y.-S.;Lin C.-H.;Chang D.-Y.;Huang C.-S.;Cheng A.-L.;Kun-Huei Yeh; Lin P.-H.; Lu Y.-S.; Lin C.-H.; Chang D.-Y.; Huang C.-S.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:42Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.;Hsu C.-H.;Chen L.-T.;Lu Y.-S.;Lin C.-H.;Yeh P.-Y.;Jeng H.-J.;Gao M.;Kun-Huei Yeh;Cheng A.-L.; Kuo S.-H.; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; KUN-HUEI YEH; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-01-19T12:08:55Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
|
André, F.; Ciruelos, E. M.; Juric, D.; Loibl, S.; Campone, M.; Mayer, I. A.; Rubovszky, G.; Yamashita, T.; Kaufman, B.; Lu, Y. S.; Inoue, K.; Pápai, Z.; Takahashi, M.; Ghaznawi, F.; Mills, D.; Kaper, M.; Miller, M.; Conte, P. F.; Iwata, H.; Rugo, H. S. |
| 臺大學術典藏 |
2021-01-15T03:47:43Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Hsu C.; Lu Y.-S.; Chang M.-C.; Lin J.-T.; HSIU-PO WANG; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:26Z |
Pneumatosis coli after etoposide chemotherapy for breast cancer
|
Shih I.-L.; Lu Y.-S.; HSIU-PO WANG; Liu K.-L. |
